Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) granted inducement stock options to three new employees under its 2025 Inducement Plan, adopted on December 24, 2025.
The awards cover an aggregate of 63,000 shares at an exercise price of $8.30 per share and were approved on May 31, 2026 under Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed, relatively modest moves (e.g., ANNX +0.93%, MNPR +1.04%, TNXP -2.38%), suggesting CADL’s action around this routine grant is stock-specific rather than part of a broad biotech swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 15 | Phase 3 follow-up data | Positive | -9.9% | Extended phase 3 CAN-2409 follow-up showed 39% disease-free survival improvement. |
| May 14 | Earnings and pipeline | Neutral | -0.3% | Q1 2026 results, strong cash of $194.8M, and plans for BLA and NSCLC trial. |
| May 13 | Investor conferences | Neutral | +2.5% | CEO participation in Stifel oncology forum and Jefferies healthcare conference. |
| May 4 | Conference call notice | Positive | +16.4% | Announcement of call to discuss extended phase 3 CAN-2409 prostate cancer data. |
| May 1 | Prior inducement grants | Neutral | +16.4% | Inducement options for 29,400 shares at $6.18 under 2025 Inducement Plan. |
Recent news skewed toward positive clinical and financing milestones, with mixed price reactions: some strong rallies on conference updates, but a notable selloff on detailed phase 3 data.
Over the last month, CADL highlighted positive phase 3 data for CAN-2409 in localized prostate cancer and reiterated plans for a Q4 2026 BLA submission, alongside Q1 2026 results and strengthened cash of $194.8M. Investor conferences and a prior inducement grant under the 2025 Inducement Plan also featured. Price reactions ranged from a -9.92% drop on extended phase 3 data to gains of 16.38% on earlier conference and inducement news, showing varied responses to both clinical and routine updates.
Regulatory & Risk Context
An effective Form S-3 shelf filed on August 14, 2025 registers up to $300,000,000 of securities, including up to $50,000,000 of common stock via an at-the-market agreement with Jefferies LLC, providing flexibility to raise capital for R&D, manufacturing, clinical trials, and corporate purposes.
Market Pulse Summary
This announcement details routine inducement stock option grants totaling 63,000 shares at an exercise price of $8.30, issued under Candel’s 2025 Inducement Plan adopted on December 24, 2025. Vesting is service-based, with 25% after one year and the remaining 75% over 36 months. In context of recent positive phase 3 data and a registered shelf of up to $300,000,000, investors may monitor how compensation, hiring, and future financings support the clinical and commercial strategy.
Key Terms
stock options financial
Nasdaq Listing Rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on May 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 63,000 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
